Nanox Reports Revenue Growth but Faces Going Concern Doubts

Event summary

Nanox reported preliminary Q3 2026 revenue of $4.3–$4.4M, up from $3.4M in Q3 2025, driven by AI/software solutions and teleradiology services.
Cash reserves dropped to $26M as of September 30, 2026, from $60M at year-end 2025, raising going concern doubts.
Nanox.AI signed a distribution deal with Technologic s.r.l. for its Bone Solution in Italy.
TIME recognized Nanox.ARC X among its Best Inventions of 2026.
AI/software revenue surged to $1M (vs. $0.1M YoY) due to Vaso Healthcare IT consolidation.

The big picture

Nanox's revenue growth highlights the demand for AI-driven medical imaging solutions, but its cash burn and going concern warning signal broader challenges in scaling hardware-heavy healthcare tech. The Italian distribution deal and TIME recognition validate its innovation, yet the company must address liquidity risks to maintain momentum. The medical imaging sector's shift toward preventive care and cloud-based diagnostics plays to Nanox's strengths, but execution will determine its long-term viability.

What we're watching

Liquidity Crisis: Whether Nanox can secure additional funding to address its going concern status and sustain operations beyond 2027.
Market Expansion: The pace at which Nanox.AI can scale through international distribution deals like the Italian partnership.
Revenue Diversification: How Nanox balances growth in AI/software solutions against declining cash reserves and operational costs.